Consolidation chemotherapy in postmolar low-risk gestational trophoblastic neoplasia: a systematic review protocol

• Published in: BMJ open Vol. 12; no. 2; p. e059484
• Main Authors: Branco-Silva, Mariza, Maesta, Izildinha, Elias, Kevin, Berkowitz, Ross Stuart, Abbade, Joelcio Francisco, Horowitz, Neil S
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 24-02-2022; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Protocol
• Subjects: Bias; Chemotherapy; Collaboration; Consolidation Chemotherapy; Cross-Sectional Studies; Female; Gestational Trophoblastic Disease - drug therapy; gynaecological oncology; Humans; Neoplasm Recurrence, Local - drug therapy; Obstetrics and Gynaecology; Patients; Pregnancy; Remission (Medicine); Research Design; Risk; Systematic review; Systematic Reviews as Topic; Womens health; United Kingdom > UK; Netherlands; chemotherapy; gynaecological oncology
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2021-059484

IntroductionCurrent evidence remains insufficient to strongly demonstrate the benefits of consolidation chemotherapy to all women with low-risk gestational trophoblastic neoplasia (GTN). This protocol outlines a systematic review to investigate whether consolidation chemotherapy is necessary for all patients with postmolar low-risk GTN after human chorionic gonadotropin normalisation with first-line single-agent chemotherapy.Methods and analysisA search string will be used to search the PubMed (MEDLINE), EMBASE, Web of Sciences, Scopus, LILACS and Cochrane Central Register of Controlled Trials databases. Articles will be screened at the title and abstract level, and then at the full article level by two independent reviewers using inclusion/exclusion criteria. Randomised and non-randomised study designs will be included, while case studies, commentaries, editorials, review articles, animal studies, basic science studies and cross-sectional studies, as well as studies not reporting relapse/recurrence rates and/or whether consolidation chemotherapy was delivered will be excluded. There will be no restrictions on date of publication, geographical location, study setting, or language of publication. The primary outcome is rate of recurrence/relapse. The assessments of randomised controlled trials will be performed using the risk of bias tool from the Cochrane Collaboration. Non-randomised studies will be assessed using the Newcastle-Ottawa scale. The quality of evidence will be assessed using the Grading quality of evidence and strength of recommendations (Grades of Recommendations, Assessment, Development and Evaluation) guidelines.Ethics and disseminationNo formal ethical approval is required as all data collected will be secondary data and analysed anonymously. Results will be disseminated through a peer-reviewed publication and at scientific events.PROSPERO registration numberCRD42020164822.